PMID- 18209581
OWN - NLM
STAT- MEDLINE
DCOM- 20080401
LR  - 20131121
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 42
IP  - 2
DP  - 2008 Feb
TI  - Evaluation of three different proton pump inhibitors with amoxicillin and 
      metronidazole in retreatment for Helicobacter pylori infection.
PG  - 139-42
LID - 10.1097/MCG.0b013e31802cbc1a [doi]
AB  - GOALS: We compared the eradication results of retreatment of eradication with 
      proton pump inhibitor (PPI) plus amoxicillin and metronidazole for patients with 
      Helicobacter pylori infection not eradicated by initial treatment with PPI plus 
      amoxicillin and clarithromycin. BACKGROUND: In Japan, the guideline proposes that 
      the use of metronidazole in a triple therapy containing PPI, PPI plus amoxicillin 
      and metronidazole is desirable in retreatment. However, there are no reports 
      comparing various retreatment using different PPIs. METHODS: After initial 
      treatment failure with a PPI plus amoxicillin and clarithromycin, 169 patients 
      were randomized to a PPI (rabeprazole, lansoprazole, or omeprazole) plus 
      amoxicillin and metronidazole given b.i.d. for 7 days. RESULTS: Pretreatment 
      susceptibility testing showed a high level of clarithromycin resistance (78%). 
      The over all eradication rates were similar with the 3 PPIs, 91.1% range 90.1 to 
      91.4 with intention-to-treat analysis. The presence of metronidazole resistance 
      reduced the eradication rate by approximately 40% (from 96.6% to 57.1%, P<0.05). 
      CONCLUSIONS: In Japan, the combination of a PPI plus amoxicillin and 
      metronidazole provide excellent eradication rates after initial treatment failure 
      with a PPI plus amoxicillin and clarithromycin. The results with metronidazole 
      resistant strains are less satisfactory and pretreatment susceptibility testing 
      may become needed if the prevalence of metronidazole resistant H. pylori 
      increase.
FAU - Murakami, Kazunari
AU  - Murakami K
AD  - Faculty of Medicine, Department of Gastroenterology, Oita University, Oita, 
      Japan. murakam@med.oita-u.ac.jp
FAU - Okimoto, Tadayoshi
AU  - Okimoto T
FAU - Kodama, Masaaki
AU  - Kodama M
FAU - Sato, Ryugo
AU  - Sato R
FAU - Watanabe, Koichiro
AU  - Watanabe K
FAU - Fujioka, Toshio
AU  - Fujioka T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 140QMO216E (Metronidazole)
RN  - 32828355LL (Rabeprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - Adult
MH  - Amoxicillin/therapeutic use
MH  - Anti-Infective Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastritis/*drug therapy/*microbiology
MH  - Helicobacter Infections/*drug therapy/microbiology
MH  - Helicobacter pylori/*isolation & purification
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Metronidazole/therapeutic use
MH  - Middle Aged
MH  - Omeprazole/therapeutic use
MH  - Peptic Ulcer/*drug therapy/*microbiology
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Rabeprazole
MH  - Retreatment
MH  - Treatment Outcome
EDAT- 2008/01/23 09:00
MHDA- 2008/04/02 09:00
CRDT- 2008/01/23 09:00
PHST- 2008/01/23 09:00 [pubmed]
PHST- 2008/04/02 09:00 [medline]
PHST- 2008/01/23 09:00 [entrez]
AID - 00004836-200802000-00005 [pii]
AID - 10.1097/MCG.0b013e31802cbc1a [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 2008 Feb;42(2):139-42. doi: 10.1097/MCG.0b013e31802cbc1a.